Survival of older adults with newly diagnosed acute myeloid leukemia: Effect of using multiagent versus single agent chemotherapy
We analyzed US National Cancer Data Base of patients aged 60-79 years, who were diagnosed with acute myeloid leukemia (AML) between 2004-2014 (n=25,621). The use of multiagent versus single-agent chemotherapy was associated with a greater 1-year overall survival (43% vs. 28%), particularly for patients aged 60-69 years, those with good-risk AML or Charlson comorbidity score of 0-1.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Vijaya R. Bhatt, Valerie Shostrom, Sarah A. Holstein, Zaid S. Al-Kadhimi, Lori J. Maness, Ann Berger, James O. Armitage, Krishna Gundabolu Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Study